1. Volpicelli JR, Alterman AI, Hayashida M. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-880.
2. Volpicelli JR. Alcohol abuse and alcoholism: an overview. J Clin Psychiatry 2001;62:Suppl 20. 4-10.
3. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004;99:21-24.
4. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA 1986;256:1449-1455.
5. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: Van evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003;13:469-475.
6. Durbin P, Hulot T, Chabac S. In: Soyka M, editor. Pharmacodynamics and pharmacokinetics of acamprosate : An overview. Acamprosate in Relapse Prevention of Alcoholism 1995;Berlin: Springer-Verlag. 47-64.
7. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 1996;53:673-680.
8. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol: Alcohol and Alcoholism. Alcohol Alcohol 1995;30:239-247.
9. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 1997;171:73-75.
10. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom multicentre acamprosate study (UKMAS): a 6 month prospective study of acamprosate vs placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35:176-187.
11. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Korean Acamprosate Clinical Trial Investigators. Acamprosate in Korean alcohol dependent patients: a multi-center, randomized, double-blind, placebo-ontrolled study. Alcohol. Alcohol Alcohol 2003;38:135-134.
12. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone. J Clin Psychiatry 1984;45:15-19.
13. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry 1995;56:Suppl 7. 24-29.
14. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Veterans Affairs Naltrexone Cooperative Study 425 Group. naltrexone in the treatment of alcohol dependence[see comment]. N Engl J Med 2001;345:1734-1739. Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial.
15. Croop RS, Labriola DF, Wroblewski JM, Nibbelink DW. A multicenter safety study of naltrexone as adjunctive pharmacotherapy for individuals with alcoholism. Presented at annual meeting of the American Psychiatric association 1995;20-25.
16. Verebey K, Volavska J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism, and effect after acute and chronic dosing. Clinical Pharmacology and Therapeutics 1976;20:315-328.
17. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. Journal of Clinical Psychopharmacology 2001;21:632-634.
18. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000;284:963-971.
19. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003;361:1677-1685.
20. Johnson BA, Swift RM, Ait DN, DiClemente CC, Javors MA, Malcolm RJ. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 2004;28:295-301.
21. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-705.
22. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000;24:1041-1049.
23. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995;90:87-99.
24. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner R, Brown J, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994;51:720-731.
25. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994;165:515-523.
26. Guardia J, Segura L, Gonzalvo B, Iglesias L, Roncero C, Cardus M, et al. A double-lind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res 2004;28:736-745.
27. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26:441-449.